Cannabinoids in Parkinson's Disease

Research output: Contribution to journalReview article

Abstract

The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (γ-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids and other receptor systems (transient receptor potential vanilloid type 1 cation channel, adenosine receptors, 5-hydroxytryptamine receptors). The improved knowledge, adding new interpretation on the biochemical interaction between cannabinoids and other signaling pathways, may contribute to develop new pharmacological strategies. A number of preclinical studies in different experimental Parkinson's disease (PD) models demonstrated that modulating the cannabinoid system may be useful to treat some motor symptoms. Despite new cannabinoid-based medicines have been proposed for motor and nonmotor symptoms of PD, so far, results from clinical studies are controversial and inconclusive. Further clinical studies involving larger samples of patients, appropriate molecular targets, and specific clinical outcome measures are needed to clarify the effectiveness of cannabinoid-based therapies.

Original languageEnglish
Pages (from-to)21-29
Number of pages9
JournalCannabis and Cannabinoid Research
Volume2
Issue number1
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Cannabinoids
Parkinson Disease
Cannabinoid Receptors
Physiological Phenomena
Aminobutyrates
Endocannabinoids
Purinergic P1 Receptors
Opioid Peptides
Serotonin Receptors
Movement Disorders
Parkinsonian Disorders
Basal Ganglia
Neurotransmitter Agents
Cations
Glutamic Acid
Dopamine
Outcome Assessment (Health Care)
Pharmacology

Keywords

  • Journal Article
  • Review

Cite this

Cannabinoids in Parkinson's Disease. / Stampanoni Bassi, Mario; Sancesario, Andrea; Morace, Roberta; Centonze, Diego; Iezzi, Ennio.

In: Cannabis and Cannabinoid Research, Vol. 2, No. 1, 01.02.2017, p. 21-29.

Research output: Contribution to journalReview article

@article{13eff8a5aa894fcd83c01a32c9c88218,
title = "Cannabinoids in Parkinson's Disease",
abstract = "The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (γ-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids and other receptor systems (transient receptor potential vanilloid type 1 cation channel, adenosine receptors, 5-hydroxytryptamine receptors). The improved knowledge, adding new interpretation on the biochemical interaction between cannabinoids and other signaling pathways, may contribute to develop new pharmacological strategies. A number of preclinical studies in different experimental Parkinson's disease (PD) models demonstrated that modulating the cannabinoid system may be useful to treat some motor symptoms. Despite new cannabinoid-based medicines have been proposed for motor and nonmotor symptoms of PD, so far, results from clinical studies are controversial and inconclusive. Further clinical studies involving larger samples of patients, appropriate molecular targets, and specific clinical outcome measures are needed to clarify the effectiveness of cannabinoid-based therapies.",
keywords = "Journal Article, Review",
author = "{Stampanoni Bassi}, Mario and Andrea Sancesario and Roberta Morace and Diego Centonze and Ennio Iezzi",
year = "2017",
month = "2",
day = "1",
doi = "10.1089/can.2017.0002",
language = "English",
volume = "2",
pages = "21--29",
journal = "Cannabis and Cannabinoid Research",
issn = "2378-8763",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Cannabinoids in Parkinson's Disease

AU - Stampanoni Bassi, Mario

AU - Sancesario, Andrea

AU - Morace, Roberta

AU - Centonze, Diego

AU - Iezzi, Ennio

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (γ-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids and other receptor systems (transient receptor potential vanilloid type 1 cation channel, adenosine receptors, 5-hydroxytryptamine receptors). The improved knowledge, adding new interpretation on the biochemical interaction between cannabinoids and other signaling pathways, may contribute to develop new pharmacological strategies. A number of preclinical studies in different experimental Parkinson's disease (PD) models demonstrated that modulating the cannabinoid system may be useful to treat some motor symptoms. Despite new cannabinoid-based medicines have been proposed for motor and nonmotor symptoms of PD, so far, results from clinical studies are controversial and inconclusive. Further clinical studies involving larger samples of patients, appropriate molecular targets, and specific clinical outcome measures are needed to clarify the effectiveness of cannabinoid-based therapies.

AB - The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (γ-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids and other receptor systems (transient receptor potential vanilloid type 1 cation channel, adenosine receptors, 5-hydroxytryptamine receptors). The improved knowledge, adding new interpretation on the biochemical interaction between cannabinoids and other signaling pathways, may contribute to develop new pharmacological strategies. A number of preclinical studies in different experimental Parkinson's disease (PD) models demonstrated that modulating the cannabinoid system may be useful to treat some motor symptoms. Despite new cannabinoid-based medicines have been proposed for motor and nonmotor symptoms of PD, so far, results from clinical studies are controversial and inconclusive. Further clinical studies involving larger samples of patients, appropriate molecular targets, and specific clinical outcome measures are needed to clarify the effectiveness of cannabinoid-based therapies.

KW - Journal Article

KW - Review

U2 - 10.1089/can.2017.0002

DO - 10.1089/can.2017.0002

M3 - Review article

C2 - 28861502

VL - 2

SP - 21

EP - 29

JO - Cannabis and Cannabinoid Research

JF - Cannabis and Cannabinoid Research

SN - 2378-8763

IS - 1

ER -